{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:48:07Z","timestamp":1782920887730,"version":"3.54.5"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) can precipitate autoimmune bullous diseases, among which bullous pemphigoid (BP) is uncommon but has significant clinical implications. We report a 72\u2212year\u2212old man with poorly differentiated gastric adenocarcinoma and liver metastases who developed generalized pruritic erythema after the 4th cycle of sintilimab, followed by tense blisters after the 8th cycle. Upon admission (January 2025), over 30% of his body surface area (BSA) was affected, accompanied by pruritus that impacted his sleep. Histopathology showed eosinophilic cell infiltration within the epidermis and mild spongiosis. Edema was observed between collagen fibers in the papillary dermis, accompanied by a small number of lymphocytes and histiocytes. Moderate (+++) mixed inflammatory cell infiltration was observed in the superficial dermis, primarily consisting of lymphocytes (approximately 60%) and eosinophils (approximately 30%), with a small number of neutrophils (approximately 10%). Direct immunofluorescence (DIF) revealed IgG and C3 along the basement membrane zone (BMZ). Serum autoantibodies demonstrated significantly elevated BP180 (392.01 RU\/mL) and low BP230 (9.29 RU\/mL), while desmoglein\u22121 (8.38 U\/mL) and desmoglein\u22123 (5 U\/mL) were negative\/low, supporting BP rather than pemphigus. The rash met the CTCAE (Common Terminology Criteria for Adverse Events) v5.0 criteria for Bullous dermatitis, Grade 3, with concomitant Pruritus, Grade 3. Daily intravenous methylprednisolone 60 mg was initiated, leading to cessation of new blister formation within 7 days and improvement in pruritus. Sintilimab was discontinued during treatment and resumed after BP was brought under control (approximately 1 month later); the patient has maintained remission for more than 12 months since resuming Sintilimab treatment, and no recurrence has been observed. The temporal association with PD\u22121 blockade, objective clinicopathologic confirmation, and lack of strong alternative culprits support a possible causal relationship. Early biopsy, DIF, and targeted serology enable timely CTCAE\u2212guided management and informed decision-making for pausing or rechallenging PD\u22121 therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1776044","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:12:45Z","timestamp":1782918765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor)"],"prefix":"10.3389","volume":"17","author":[{"given":"Chang","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutaneous Med Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13637","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"van Beek","year":"2018","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol JDDG"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Annals"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15638","article-title":"Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis","volume":"23","author":"Pruessmann","year":"2025","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol JDDG"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115252","article-title":"Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events","volume":"217","author":"Rosnev","year":"2025","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: A systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363032","article-title":"State-of-the-art diagnosis of autoimmune blistering diseases","volume":"15","author":"van Beek","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent advances in understanding pemphigus and bullous pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14097","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update","volume":"18","author":"Schmidt","year":"2020","journal-title":"J der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol JDDG"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s374449","article-title":"A case of systemic severe bullous pemphigoid caused by long-term sintilimab treatment for renal cell carcinoma","volume":"15","author":"He","year":"2022","journal-title":"Clinical Cosmetic Investigational Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1124730","article-title":"Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR\/MSS colorectal cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000041448","article-title":"Sintilimab-induced photodistributed bullous pemphigoid: A case report","volume":"104","author":"Cui","year":"2025","journal-title":"Medicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639287","article-title":"Long-term survival benefit from third-line treatment for advanced colon cancer: A case report","volume":"16","author":"Su","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1776044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:12:50Z","timestamp":1782918770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1776044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1776044"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1776044","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1776044"}}